Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016082852> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W2016082852 endingPage "940" @default.
- W2016082852 startingPage "934" @default.
- W2016082852 abstract "Amlodipine and valsartan have different mechanisms of action, and it is known that the combination therapy with the 2 drugs increases treatment effects compared with the monotherapy with each drug. A fixed-dose combination (FDC) drug is a formulation including fixed amounts of active drug ingredients combined in a single dosage form that is expected to improve medication compliance.The goal of this study was to compare the pharmacokinetic profiles of single administration of a newly developed FDC tablet containing amlodipine orotate 10 mg and valsartan 160 mg (test formulation) with the conventional FDC tablet of amlodipine besylate 10 mg and valsartan 160 mg (reference formulation) in healthy male Korean volunteers.This was a randomized, open-label, single-dose, 2-way crossover study. Eligible subjects were between the ages of 20 and 50 years and within 20% of their ideal weight. Each subject received a single dose of the reference and the test formulations, with a 14-day washout period between formulations. Blood samples were collected up to 144 hours after the dose, and pharmacokinetic parameters were determined for amlodipine and valsartan. Adverse events were evaluated based on subject interviews and physical examinations.Forty-eight of the 50 enrolled subjects completed the study. For both amlodipine and valsartan, the primary pharmacokinetic parameters were included in the range for assumed bioequivalence, yielding 90% CI ratios of 0.9277 to 0.9903 for AUC(0-last) and 0.9357 to 1.0068 for C(max) in amlodipine, and 0.9784 to 1.1817 for AUC(0-last) and 0.9738 to 1.2145 for C(max) in valsartan. Dizziness was the most frequently noted adverse event, occurring in 4 subjects with the test formulation, followed by oropharyngeal pain occurring in 1 subject with the test formulation and 3 subjects with the reference formulation. All other adverse events occurred in <3 subjects.These findings suggest that the pharmacokinetics of the newly developed FDC tablet of amlodipine and valsartan did not differ significantly from the conventional FDC tablet in these healthy Korean male subjects. Both formulations were well tolerated, with no serious adverse events observed. ClinicalTrials.gov identifier: NCT01823913." @default.
- W2016082852 created "2016-06-24" @default.
- W2016082852 creator A5008592527 @default.
- W2016082852 creator A5015440064 @default.
- W2016082852 creator A5016363463 @default.
- W2016082852 creator A5027028606 @default.
- W2016082852 creator A5028724756 @default.
- W2016082852 creator A5073604371 @default.
- W2016082852 creator A5075616189 @default.
- W2016082852 creator A5089667014 @default.
- W2016082852 date "2013-07-01" @default.
- W2016082852 modified "2023-10-18" @default.
- W2016082852 title "Pharmacokinetic Comparison of 2 Fixed-Dose Combination Tablets of Amlodipine and Valsartan in Healthy Male Korean Volunteers: A Randomized, Open-Label, 2-Period, Single-Dose, Crossover Study" @default.
- W2016082852 cites W140391610 @default.
- W2016082852 cites W2003548132 @default.
- W2016082852 cites W2012154384 @default.
- W2016082852 cites W2056189228 @default.
- W2016082852 cites W2120330210 @default.
- W2016082852 cites W4292329040 @default.
- W2016082852 cites W7687383 @default.
- W2016082852 doi "https://doi.org/10.1016/j.clinthera.2013.05.021" @default.
- W2016082852 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23870605" @default.
- W2016082852 hasPublicationYear "2013" @default.
- W2016082852 type Work @default.
- W2016082852 sameAs 2016082852 @default.
- W2016082852 citedByCount "9" @default.
- W2016082852 countsByYear W20160828522015 @default.
- W2016082852 countsByYear W20160828522016 @default.
- W2016082852 countsByYear W20160828522017 @default.
- W2016082852 countsByYear W20160828522019 @default.
- W2016082852 countsByYear W20160828522020 @default.
- W2016082852 countsByYear W20160828522021 @default.
- W2016082852 crossrefType "journal-article" @default.
- W2016082852 hasAuthorship W2016082852A5008592527 @default.
- W2016082852 hasAuthorship W2016082852A5015440064 @default.
- W2016082852 hasAuthorship W2016082852A5016363463 @default.
- W2016082852 hasAuthorship W2016082852A5027028606 @default.
- W2016082852 hasAuthorship W2016082852A5028724756 @default.
- W2016082852 hasAuthorship W2016082852A5073604371 @default.
- W2016082852 hasAuthorship W2016082852A5075616189 @default.
- W2016082852 hasAuthorship W2016082852A5089667014 @default.
- W2016082852 hasBestOaLocation W20160828521 @default.
- W2016082852 hasConcept C112705442 @default.
- W2016082852 hasConcept C126322002 @default.
- W2016082852 hasConcept C142724271 @default.
- W2016082852 hasConcept C197934379 @default.
- W2016082852 hasConcept C204787440 @default.
- W2016082852 hasConcept C27081682 @default.
- W2016082852 hasConcept C2776623344 @default.
- W2016082852 hasConcept C2777387769 @default.
- W2016082852 hasConcept C2779646130 @default.
- W2016082852 hasConcept C42404028 @default.
- W2016082852 hasConcept C71924100 @default.
- W2016082852 hasConcept C84393581 @default.
- W2016082852 hasConcept C87813604 @default.
- W2016082852 hasConcept C98274493 @default.
- W2016082852 hasConceptScore W2016082852C112705442 @default.
- W2016082852 hasConceptScore W2016082852C126322002 @default.
- W2016082852 hasConceptScore W2016082852C142724271 @default.
- W2016082852 hasConceptScore W2016082852C197934379 @default.
- W2016082852 hasConceptScore W2016082852C204787440 @default.
- W2016082852 hasConceptScore W2016082852C27081682 @default.
- W2016082852 hasConceptScore W2016082852C2776623344 @default.
- W2016082852 hasConceptScore W2016082852C2777387769 @default.
- W2016082852 hasConceptScore W2016082852C2779646130 @default.
- W2016082852 hasConceptScore W2016082852C42404028 @default.
- W2016082852 hasConceptScore W2016082852C71924100 @default.
- W2016082852 hasConceptScore W2016082852C84393581 @default.
- W2016082852 hasConceptScore W2016082852C87813604 @default.
- W2016082852 hasConceptScore W2016082852C98274493 @default.
- W2016082852 hasIssue "7" @default.
- W2016082852 hasLocation W20160828521 @default.
- W2016082852 hasLocation W20160828522 @default.
- W2016082852 hasOpenAccess W2016082852 @default.
- W2016082852 hasPrimaryLocation W20160828521 @default.
- W2016082852 hasRelatedWork W1829710777 @default.
- W2016082852 hasRelatedWork W2016082852 @default.
- W2016082852 hasRelatedWork W2038119104 @default.
- W2016082852 hasRelatedWork W2076017860 @default.
- W2016082852 hasRelatedWork W2354984853 @default.
- W2016082852 hasRelatedWork W2361141970 @default.
- W2016082852 hasRelatedWork W2891834114 @default.
- W2016082852 hasRelatedWork W3107920033 @default.
- W2016082852 hasRelatedWork W3175896874 @default.
- W2016082852 hasRelatedWork W4205128092 @default.
- W2016082852 hasVolume "35" @default.
- W2016082852 isParatext "false" @default.
- W2016082852 isRetracted "false" @default.
- W2016082852 magId "2016082852" @default.
- W2016082852 workType "article" @default.